Avesta's approach involves working with patients' mental health providers to tailor treatments to individual needs.

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.